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Background: Breast Cancer is the most common cancer amongst wāhine in Aotearoa, 
with approximately 3,300 diagnoses every year. Breast reconstruction after breast cancer 
treatment (e.g. mastectomy) is an important part of the overall treatment process. 
Autologous Fat Grafting (AFG) is an increasingly popular breast reconstruction option 
with minimal risks. However, a major caveat of AFG is only 30% of the original fat graft 
retained in the recipient site. Fat graft retention is regulated by the tissue 
microenvironment involving complex cross-talk between Adipose derived stem cells 
(ADSCs) in the donor site and fibroblasts cells in the breast cavity. The release of 
extracellular vesicles (EVs) from ADSCs is one signalling pathway between these two 
sites and investigating this dynamic further could help to improve fat graft retention.  
 
Aim: The aim of this study was to investigate the role of ADSC-EVs on human dermal 
fibroblast wound healing activity in vitro.  
 
Methods: Adipose tissue samples were collected from three patients undergoing an AFG 
procedure at Wellington Regional Hospital and digested using collagenase. EVs were 
isolated from ADSCs using size exclusion chromatography (SEC) on a qEV10/35nm 
column with an automated fraction collector. ADSC-EVs were added to fibroblast cells 
(CCD-1128Sk) for 48 hrs. Following incubation fibroblast proliferation was measured 
using Cell counting kit-8, wound migration using a scratch-wound assay and mRNA 
expression levels using RT-qPCR at 0, 24 and 48 hr time points in ADSC-EVs co-
cultures. Dummy EVs which were collected from ADSC media with no cells were used 
as a negative control against ASDC-EVs. Statistical Analysis of results were compared 
using a paired t-test and deemed significant if (p <0.05). 
  
Results: ADSC-EVs show trends towards promoting a pro-inflammatory environment 
with IL-6 trending towards an increased expression in ADSC-EV co-cultures (6.556 + 
6.512; p= 0.2775) and a decrease in ACTA2 expression (0.5328 + 0.3200, p= 0.1272). 
Based on standard deviation assessment, ADSC-EV co-cultures exhibited numerically 
larger levels of variation in gene expression compared to DEVs. Cell proliferation was 
not significantly different between ADSC-EV (0.8319 + 0.340) and DEV (0.8067 + 
0.2757) co-cultures (p= 0.6290). EVs had no significant effect on cell migration 
compared to DEVs at 24 and 48 hr time points (p= 0.8976, 0.4931 respectively).  
 
Conclusion: ADSC-EVs show a trend towards promoting a pro-inflammatory 
environment in human dermal fibroblast cells, potentially influencing fibroblast function. 
ADSC-EVs also showed large levels of variation in gene expression compared to DEVs. 
This suggests that primary ADSC-EVs from patients have diverse effects and further 
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1.1 Breast Cancer – Prevalence, Treatment and Survival rates 
1.1.1 Prevalence of Breast Cancer  
Breast cancer is the most common cancer in women worldwide, with nearly 2.3 million 
women diagnosed in 2020 (1). As of December 2020, there were 7.8 million women alive 
who were diagnosed with breast cancer in the past 5 years, making it the world’s most 
prevalent cancer. Approximately 3,300 women on average are diagnosed with breast 
cancer in Aotearoa (NZ) per year (1). Additionally, Māori women in NZ are 28% more 
likely to be diagnosed with breast cancer than non-Māori (2). 
1.1.2 Treatment Options 
There are multiple treatment options available for breast cancer patients. Many of these 
options are highly effective, particularly when the disease is identified early (3). The 
treatment options include surgery and radiation for locoregional control of the disease in 
the breast, lymph nodes and surrounding areas, as well as systemic therapy such as 
chemotherapy and hormone therapy (4). Many of these treatments are combined 
depending on the condition and treatment needs of the patient. Treatment of breast cancer 
depends on the size of the tumour lesion, hormone receptivity and histologic markers, 
the presence or absence of metastatic or contralateral disease, patient age and patient 
preference (5). Common surgical treatments are used to remove cancer from the breast 
and may include lumpectomy, partial mastectomy, or total mastectomy (4). Surgical 
treatment for women with invasive breast cancer includes either breast-conserving 
surgery or mastectomy (6). Patients who undergo a mastectomy or lumpectomy are 
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referred for breast reconstruction surgery to improve aesthetic and psychosocial 
morbidity associated with these surgeries (4). Due to advancement in breast cancer 
diagnosis and treatment regimens, the 5-year survival rate is now at 90% for women in 
developed or high income countries including NZ (3, 4). With an increase in breast cancer 
survivors the need to support this group of patients has grown.  
1.2 Breast Reconstruction  
Patients undergoing a lumpectomy, partial mastectomy or total mastectomy are 
commonly recommended a referral for breast reconstruction (7). The aim of breast 
reconstruction surgery is to rebuild the shape of the breast correction (7). Patients who 
receive radiation therapy or surgery often experience great physical pain during 
treatment. Additionally, the absence of a breast can have a significant impact on a 
patient’s self-confidence and their physical and mental well-being (8). Previous research 
shows that receiving breast reconstruction helps to improve the quality of life of breast 
cancer patients and has therefore become a vital part of the breast cancer treatment 
pathway (9). 
1.2.1 Current Options and Limitations 
There are three key breast reconstruction techniques available in NZ, flap-based 
reconstruction, implant-based reconstruction and autologous fat grafting reconstruction. 
Table 1 outlines the advantages and disadvantages of each of these options. There are 
many factors to consider when determining the appropriate option for any given patient 
including, the type of treatment received by the patient and the patient’s background, risk 
factors and preference.  
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Flap-based  Ideal aesthetic appearance 
and feel (10)  
 
 Can be performed 
immediately after treatment 
(11)  
 Complex procedure (9) 
 
 Contraindications; T2DM 
and obesity (12)  
 
 Possible muscle weakness 
and movement affected (9)  
Implant-based 
 
 Simpler procedure and 
shorter recovery time (13)  
 
 Can be performed 
immediately or delayed after 
treatment (14)  
 
 Rare development of 
anaplastic large cell 
lymphoma (15)  
 
 Capsular contracture (16)  
Autologous 
Fat Grafting 
 Use natural tissue instead of 
implant based surgery (17)  
 
 Low surgical risk and donor 
morbidity (17, 18) 
 Low retention rates (19)  
 








Figure 1 Current Breast Reconstruction Options in Aotearoa 
A) Implant-based reconstruction of the breast uses silicone gel sacs to remodel the breast after 
breast cancer treatment. FLAP-based uses muscle tissue which can be sourced from the belly, 
back or the buttocks. B) Autologous Fat Grafting (AFG) for breast reconstruction extracts fat 
tissue through liposuction, processed through centrifugation and transferred into the recipient 
breast site through injection. 
 
 
Breast reconstruction with flap surgery utilises muscle tissue by transfer to the breast 
cavity to create a new breast mound. This option is preferred by many women as flap-
based surgery provides a more natural feel and look compared to implants (10). However, 
as Table 1 illustrates, flap-based reconstruction is time-consuming and a more complex 
procedure. As a result, flap-based reconstruction has higher levels of post-reconstruction 
complications, including potential muscle weakness, movement and tissue flap necrosis 
(20), compared with other reconstruction options. Furthermore, flap-based surgery is not 
an available option for patients with existing comorbidities such as obesity, type II 
diabetes (T2DM) or those that smoke (7). This is an issue for Māori and Pasifika women 
in NZ in particular who are high rates in these comorbidities, and therefore are less likely 
than non-Māori to have this option available to them (21).  
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Implant-based surgery option is more simple and has lower risk of surgical complications 
(13). However, the implants based reconstructions option does have long-term risks 
including, 1) the possibility of growing an associated-anaplastic large cell lymphomas as 
well as rupturing of the implant - which has shown to cause significant stress and anxiety 
amongst breast cancer patients despite its rare chance of occurrence (15) and, 2) where 
the patient’s body and immune system responds to the foreign material (implant). Here 
the collagen-fibre capsule shrinks, causing the body to form fibrous scar tissue, tightening 
and compressing the breast implant (16).  
1.2.2 Autologous Fat Grafting  
Growing in popularity amongst breast cancer patients is the third option, autologous fat 
grafting breast reconstruction (AFG). AFG is where fat tissue is removed from one site 
of the body, usually your thigh, abdomen or buttocks, by liposuction and transferred to 
another recipient site on the body (Figure 1) (22). Fat graft is processed to eliminate fluid, 
blood, cell fragments and oil for reinjection into the recipient site by injection or 
implantation (23). Beyond breast reconstruction surgery, AFG is widely used in different 
clinical procedures including aesthetic surgery, treating scars, radio-dermatitis and others 
(24). Fat is a readily available tissue that does not trigger an immune response or cause 
significant donor site morbidity when harvested (25).   
The use of AFG is increasing in popularity due to its minimal associated risks and ability 
to improve skin quality and sensation of the breast (26, 27). Multiple studies have also 
reported on AFG as an effective treatment for post-mastectomy pain syndrome by scar 
entrapment release and anatomical remodelling (28). Another main benefit of AFG is 
that more patients have access to this option, for example, it is considered a safe option 
for those who have existing comorbidities like obesity and T2DM that would currently 
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not be able to undertake flap-based reconstruction. Therefore AFG provides a more 
equitable and accessible option for Māori and Pasifika women (25). 
Despite AFG’s widespread use, one of the main limitations when grafting fat tissue is the 
varying low retention rates. Studies have shown varying percentages of fat graft survival 
rate, with as little as 30% of the initial graft amount retained in the recipient site (21). 
This unfortunately requires patients to undergo multiple surgeries in order to acquire the 
desired aesthetic result. Therefore, AFG cannot be currently used alone but in 
combination with other reconstruction techniques to achieve full breast reconstruction 
(21). 
There have been multiple efforts to improve fat graft survival by exploring different 
aspects of the AFG process. Investigation into the donor site of the fat graft and the 
different harvesting methods and processing techniques have been explored in the aim to 
develop best removal methods, minimise contamination of debris in fat transfer and 
subsequent survival of the adipose tissue that comprises the donor fat graft. However, 
these processes and techniques between surgeons and institutions are variable. A 
consistent, standard method is still yet to be developed.   
There is still minimal knowledge on what consistently contributes to poor retention rates 
in fat grafting however, it is likely that a successful integration of fat graft is dependent 
on both the grafted tissue (taken from the donor site) and the breast tissue 
microenvironment (recipient site or site where the tissue is grafted). The tissue 
microenvironment consists of a dynamic population of both cellular and non-cellular 
components which form a multifaceted regulatory network that helps to maintain the 
homeostasis of an organ and therefore involves complex cross-talk between multiple cell 
types within a 3D structure (29). A better understanding of the fat graft microenvironment 
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in which engraftment takes place is a critical aspect to improvement of retention 
outcomes.  
1.3 Fat Graft Microenvironment  
1.3.1 Adipose Tissue 
Adipose tissue is a specialised connective tissue containing fat-enriched cells called 
adipocytes and supported by other non-adipocyte cells that collectively form the stromal 
vascular fraction (SVF) (3). The SVF consists of a variety group of cells including, 
adipose derived (mesenchymal stromal) stem cells, pre-adipocytes, endothelial precursor 
cells, endothelial cells and immune cells.  
For a long time, adipose tissue was known as a passive layer/organ and was only involved 
in energy storage but research has shown that it plays an active role in signalling 
pathways (30). Adipose tissue is now recognised as an active endocrine organ that 
influences immunological processes, metabolism and cell signalling (31). Cytokines such 
as TNF-α, IL-6, MMP-9, IL-6 and TGF-β1 are some examples of factors released from 
SVF-adipose tissue that allow for signalling within the immune system (31). 
Previous research looking into improving AFG retention included manipulating cells in 
the tissue microenvironment by enriching the SVF in the fat graft. Immunofluorescence 
staining revealed that SVF cells can not only survive in an environment limited in blood 
supply such as the fat graft but also contribute to the process of angiogenesis and 
adipogenesis (32). Overall fat graft retention improved after enrichment of SVF, however 
across the board, results have varied and initial follow up studies have started to give 
credit to stem cells in the adipose tissue as the driving angiogenic force in fat graft 




Multipotent stem cells exist within a variety of tissues, including bone marrow, synovial 
membranes, amniotic membranes and adipose tissue (34). There are different 
terminologies to describe ADSCs but they are commonly recognised as a mesenchymal 
population of cells making up approximately 10% of the SVF component of adipose 
tissue (34). ADSCs are also defined by their ability to differentiate into cell types such 
as adipocytes and the expression of specific markers such as CD44, similar to 
mesenchymal stem cells (35). ADSCs have shown to improve fat graft survival due to 
their proliferative function and differentiation ability promoting angiogenesis (36). While 
efforts to enrich fat grafts with ADSCs have started to show improvements there is still 
minimal knowledge on the mechanisms they undertake. Studies in animals looked at the 
effects of enriching ADSCs in the fat graft and showed to improve retention rates by 
observing new fat produced near the site of the fat graft implantation (37). This shows 
that ADSCs can have multiple signalling mechanisms either by directly differentiating 
into new adipocytes that promote regeneration of tissue or paracrine signalling, in which 
recent studies have shown to favour the latter. Enriching ADSCs in fat graft showed to 
also alter inflammation as well as promote angiogenesis and subsequent 
revascularisation.  
As mentioned fat graft survival is thought to be dependent on how ADSCs communicate 
and influence the other cell types in the microenvironment of the fat graft (38). Many of 
ADSCs’ effects appear to be due to paracrine factors, which requires further investigation 
into the components that comprise the ADSCs signalling mechanisms. There is growing 
evidence to suggest that ADSCs wield most of their signalling to surrounding 
environments through the release of extracellular vesicles (EVs).  
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1.3.2.1 Extracellular Vesicles Derived from ADSCs 
EVs are lipid bound vesicles secreted from cells into the extracellular space and contain 
various proteins and receptors derived from the cell of origin.  Many different cell types 
including ADSCs secrete EVs (39) which contain active molecular cargo such as DNA 
and RNA that is transferred to neighbouring cells (40).  EVs including exosomes and 
microvesicles range from 40 to 600 nm in size and are able to travel via the lymphatic or 
blood systems, showing their multiple cellular cross-talk strategies (33). Even though the 
generic term EV is currently in use to refer to all secreted membrane vesicles, they are 
heterogeneous which is a significant factor in how there is slow progress in 
characterisation and understanding the use and function of EVs (30).  
As ADSCs are easily acquired from human patients, an advantage of using ADSC-EVs 
includes how expandable they are and their roles in intracellular communication (40). 
There is increasing evidence in animal studies that the regenerative effect of stem cells 
is also mediated through EVs and account for the proangiogenic potential in ADSCs (41). 
Recently, an increasing number of studies have revealed that ADSC-EVs could promote 
proliferation, tube formation, and migration of human vascular endothelial cells (42). In 
addition, ADSC-EVs modulate several molecular signalling pathways such as the AKT 
and ERK signalling pathways by elevating phosphorylation levels (43). ADSC-EVs in 
animal models also promote attenuated inflammation in fat grafts which is thought to 
have an impact on the reabsorption of fat graft in the recipient site (32). Although ADSC-
EVs’ specific function in AFG retention is not well known, EVs are known to have an 
effect on endothelial cells by influencing their proliferation and migration. EVs also have 
an effect on macrophages by modulating markers involved in an inflammatory response 
such as TGF-β1, IL-6, FAP and MMPs. This demonstrates the role ADSC-EVs have in 
mitigating inflammation and potentially reducing fat graft re-absorption (44). 
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At present, there is considerable research on how ADSC-EVs influence angiogenesis 
(endothelial cells) and inflammatory cells (macrophages). However, there is minimal 
information on their effect on fibroblasts and fibrotic processes, which could have an 
effect on post-radiation therapy scarring, fibrosis and pain (8). EVs are known to have an 
effect on fibrotic functional outputs, but more research is required to understand what 
effect of ADSC-EVs on fibroblast function in a fat graft environment. 
1.4 Breast Tissue Microenvironment  
1.4.1 Wound healing in the Breast Cavity  
A healthy breast is made of several types of tissue, including glandular, adipose and 
fibrous connective tissue. Therefore, the breast microenvironment consists of adipocytes, 
adipose-derived stem cells (ADSCs), epithelial, immune and other stromal cells (3). The 
breast extracellular matrix (ECM) is a dynamic scaffold of connective tissue that support 
and regulate intercellular communication and cell proliferation, migration and 
differentiation (45). The breast cavity microenvironment is likely altered by surgical 
resection and radiation therapy due to increased inflammation and fibrotic processes as a 
result of these treatments. (3, 46). Radiotherapy following surgery is an effective method 
of ensuring the eradication of cancer cells, however also causes necrosis in the breast 
tissue and stimulates an immune reaction (47). The increased presence of inflammatory 
and ECM regulatory cells could have a role in how the fat graft is retained in the breast 
cavity and fibroblasts are critical cell type involved in the wound repair response.  
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1.4.2 Fibroblast Cell Function in Breast Tissue 
Wound healing is a complex process in the body where the end goal is to replace and 
restore damaged tissue. Breast fibroblasts are an important cell type in wound healing 
and play a central role in restoring the integrity of injured tissue post-treatment (48). 
Under normal physiological conditions, fibroblasts are in a quiescent state and involved 
in regulating ECM homeostasis through the production of extracellular matrix proteins 
such as collagen and glycosaminoglycan structures.  
When there is tissue damage or biomaterial implantation, fibroblasts are activated and 
transdifferentiate into a specialised myofibroblast phenotype. This activated phenotype 
is the hallmark for fibrotic disease as elevated ECM production occurs leading to the 
pathological fibrotic accumulation of ECM characterised by increased alpha smooth 
muscle actin (αSMA/ACTA2) protein/gene expression levels (49). Stimuli that activate 
the fibroblasts such as TGF-β1, COL1A1, IL-6, and FAP generally derive from 
macrophages and therefore induce an inflammatory reaction (50). The inflammatory 
response as a result initiation of tissue repair, involves an extensive network of cellular 
connections from macrophages, and other molecules such as lipid mediators and growth 
factors (51). Due to fibroblast activation and function in the pro-inflammatory, 
proliferative and remodelling phase of wound healing, fibroblast cells are involved in 
key processes such as breaking down the fibrin clot, creating new extra cellular matrix 
(ECM) structures to support the other cells associated with effective wound healing, as 
well as contracting the wound once inflammation decreases (39).  
Ensuring fat graft integration into the breast microenvironment as part of AFG will 
depend on fibroblast’s pro-inflammatory, pro-fibrotic phenotypes roles and regulation in 
wound healing. More specifically, their role in ECM remodelling and inflammatory 
response make them an important cell of interest to investigate for AFG retention.  
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1.5 Aims of the research and Hypothesis 
 
The overall aim of this work is to investigate the role that ADSC-EVs have in AFG 
retention. This involves an initial aim to comprehensively study on what effects ADSC-
EVs could have on multiple cell types present in the recipient breast tissue of fat grafts. 
This was initially done by looking at individual cell types and culture models to measure 
any changes in activity or function in these cells. The current study builds on previous 
work in the lab that has successfully isolated ADSCs from adipose tissue and started to 
look at another cell type found in the breast cavity. To the best of our knowledge, this is 
the first study that is looking at ADSC-EV effects on human fibroblast cells in culture. 
We therefore hypothesise that ADSC-EVs will have a role in the wound healing response 




2 Materials and Methods 
2.1 Ethical Approval and Considerations 
2.1.1 Ethical Approval and Patient Consent 
This study has ethical approval from the Health and Disabilities Ethics Committee 
(HDEC; 19/CEN/23). Fat tissue samples were collected from 14 patients between April 
and October 2021. Of these samples, three were included in this study. Patients were 
recruited who had a history of breast cancer and were undergoing an AFG procedure at 
Wellington Regional Hospital and Kenepuru Hospital. Participants were excluded from 
the study if they were younger than 18 years of age, were unable to consent or declined 
a fat grafting surgery.  
All eligible patients were consented by the researcher or another member of the research 
team (Surgical Cancer Research Group, UOW) prior to their surgery. Patients and their 
whānau were told that participation was voluntary, that the participant was free to 
withdraw from the study at any time and declining to participate at any point would not 
impact their overall medical care and treatment. Participants provided written informed 
consent to collect adipose tissue samples during their surgery and for the researcher to 
collect demographic and clinicopathologic information from patient medical records. 
2.1.2 Patient Demographic, Clinical, and Pathological Characteristics  
To maintain patient confidentiality each participant was assigned a unique study 
identification code and information was stored in a de-identified, password-protected 
database on a secure University of Otago server (REDCap). 
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The demographic information collected prospectively included; age, gender, ethnicity 
and Body Mass Index (BMI) and stored in the REDCap database. Patient’s pathological 
information was also collected and included; type of breast cancer, stage, grade, which 
breast was affected, type of treatment/s undertaken for breast cancer and if patient had 
any previous reconstruction surgeries.  
2.1.3 Māori Cultural Consideration 
The overall project that this study is connected to had previously undertaken consultation 
processes with the Research Advisory Group Māori at CCDHB and Ngāi Tahu through 
Otago University.  
It was important to me as a Māori researcher to take into account and uphold tikanga 
māori when there is a need especially considering participants. I undertook Tikanga 
māori Research training through the Māori Research Advisory Group at Wellington 
Hospital. I am also entrenched in te ao Māori and understand the significance of 
providing a safe space for Māori to pariticpate in health research in a mana-enhancing 
manner. Tikanga Māori was incorporated into this study as an acknowledgement of 
cultural beliefs around Te Tuku i te Taonga/sharing the gift i.e. donating human tissue. 
For example patients were offered to have their tissue disposed of with the use of an 
appropriate karakia (blessing) or the standard hospital disposal method. This coincides 
with the values of Te Hau o te Taonga (the spirit of the gift) as human tissue is considered 
tapu (sacred) given its connection to whakapapa (genealogy). Participants were also 
offered to be informed of results found from the study once available for dissemination. 
This embodies the value of Te Whakahoki i te Taonga, not only the return of the gift but 
respect for the relationship built and provides an opportunity to report on all uses of the 
matauranga (knowledge in the form of data) gathered. 
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2.2 Adipose Derived Stem Cells (ADSCs) 
2.2.1 ADSC Isolation  
Adipose tissue was collected at Wellington and Kenepuru Hospital at the time of patient’s 
procedure and ADSCs were isolated in the lab within 60-80 minutes. ADSC isolation 
and culture protocols had already been established in the lab previously. That prior work 
has confirmed that these cells are positive for CD166+, CD105+, CD10+ markers and 
negative for CD31-, CD14- markers confirming that they are ADSCs. After collection, 
tissue samples were taken to an Otago University, Wellington lab, washed and digested 
with PBS and collagenase (diluted to 0.1% / 0.075% in PBS) for 35-40 minutes on a 
shaking incubator at 370C. After tissue digestion, samples were centrifuged at 1000 x g 
for 4 minutes. The supernatant was removed and the adipose-derived Stromal Vascular 
Fraction (SVF) pellet was re suspended in ADSC cell culture media (DMEM; 10% FBS; 
1% Penicillin-Streptomycin). Centrifugation and resuspension steps were repeated and 
then cell viability was determined by staining cells with 0.4 % Trypan blue solution 
(Sigma Aldrich) and counted using a haemocytometer (LUNA Automated cell counter). 
Cells were re-suspended in 5 ml of media and plated in a T25 flask (In Vitro 
Technologies) at >1 x 106 cells/mL. Cells were incubated at 370C with 5% carbon dioxide 
(CO2) and culture media was changed every 48 hrs until cells reached 80 – 90 % 
confluence.  
2.2.2 ADSC Cell Culture 
Once confluent, cells were passaged to a T75 flask (In Vitro Technologies) by removing 
media from flask, washing twice with PBS, adding 0.25% trypsin-EDTA and incubating 
at 370C until cells detached. Culture media was added to trypsin to stop its proteolytic 
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enzyme activity in dissociating the adherent ADSCs and cells were centrifuged at 1000 
x g for 4 mins. The supernatant was discarded and the cell pellet was re-suspended in 
fresh cell culture media and quantified with 0.4% Trypan blue using a haemocytometer 
and plated in a T75 flask at 1.0 x106 cells/ mL. Cells were cultured until passage 5 (P5). 
ADSC-EV media was collected from passages 2, 3 and 4 as previously established in the 
lab as an optimal range before ADSCs were shown to be senescence which would affect 
EV output. Following passaging, cells were centrifuged at 2000 x g for 10 mins to clear 
debris, and slow freeze our samples to prevent EV bursting and maintain membrane 
integrity then stored in -800C.  
2.3 Extracellular Vesicles  
2.3.1 Isolation of Adipose-Derived Stem Cell Extracellular Vesicles  
ADSC-EV media from ADSC cell cultures were thawed at 37oC in a water bath and 
centrifuged at 2000 x g for 10 minutes to pellet any potential debris. EVs were isolated 
from the supernatant using Size Exclusion Chromatography (SEC), where molecules in 
the ADSC-media were separated based on their size. Samples were run through a size 
exclusion qEV10/35nm column on an automated fraction collector (Izon Science, 
Christchurch, New Zealand). ADSC-EVs were isolated and collected in 4 x 5ml fractions 
following a 20 mL void (PBS) volume. Columns were washed between uses with 120 
mL PBS and used a maximum of 10 times. Flow rate was also measured between each 
consecutive sample to ensure there was no column clogging. Following isolation, 
fractions were pooled together for each patient and concentrated by centrifuging at 4000 
x g for 30 – 40 mins using Amicon Ultra-15 Centrifugal Filter Units with Ultracel-100 
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membrane (Lab Supply) and re-suspended to 100 µL. Aliquots were used for both size 
concentration analysis on qNano and also for downstream fibroblast co-cultures. 
2.3.2 Confirmation of EV Characteristics using TRPS 
Size and concentration of ADSC-EVs was determined using tuneable resistive pulse 
sensing (TRPS) with the qNano Gold (Izon). Standard protocols from the manufacturer 
were followed for the use of qNano. All samples were run through a tuneable submicron-
sized pore NP200, with a target size range of 100 - 400 nm (NanoPore; Izon) that 
separates the two fluid chambers: one containing the sample (EV concentrate), the other 
an electrolyte solution (PBS-containing wetting solution). The pore was stretched 
between 47.1- 47.3 mm and then particles driven through by an electric current using 
voltages between 0.32 and 0.36 V and pressure of 10-15 kPa. Each particle causes a 
resistive pulse or blockade signal that is detected and measured. CPC200 polystyrene 
calibration beads (Izon) that complement the nanopore were diluted 1:200 in PBS, 
vortexed briefly to ensure homogeneity and used to calibrate ADSC-EV samples. To 
quantify particle concentration and size, isolated ADSC-EVs stored in -80oC were 
thawed at 370C in a water bath, centrifuged at 2000 x g for 5 mins and measured 
undiluted. Samples were run until a particle count of at least 500 was reached (particle 
rate of <100/min, duration of run at least 5 mins). EV concentration and size (by mean 
and mode) were measured using Izon Control Suite, version 3.3 and presented these 
findings in the form of histograms, rate plots and signal trace graphs in relation to 




Figure 2 Representative signal trace of ADSC-EVs 
Representative signal trace of current in nanoamps (nA) versus time in seconds (s) for ADSC-
EVs extracted from ADSC culture media sample. The current spikes represent the disruption or 
blockage of each passing particle as the EVs flow through the NP200 nanopore at a voltage 
0.34 V, stretch of 47.2 nm and pressure 10-15 kPa. 
 
 
Application of ADSC-EVs to recipient cells 
A 2-step dilution was performed due to the low proportion of EV concentrate used 
compared to the culture media. EVs were initially diluted to 1 x 106 EVs/mL and then 1 
x 105 EVs/mL. ADSC-EVs were applied directly to recipient cells at 1 x105 EVs per mL 
of media. This is based on dose-response experiments on other cell types that have found 
this is a dose that is sufficient to produce measureable for 24 hrs prior to measuring the 
effects. Dummy EVs (DEVs) were used as a negative control for all experimental assays. 
DEVs are the cell culture media, which is run through SEC column and were also added 
to fibroblast cells at an equivalent volume to the ADSC-EVs.  
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2.4 Fibroblast Cell Culture  
2.4.1 Skin Fibroblast Cell Culture 
Human Fibroblasts (CCD1128SK) were obtained from ATCC and were available in the 
lab prior to Honour’s project commencing. Fibroblasts were cultivated in IMDM 
supplemented cell culture media. Fibroblast cell cultures were incubated in a humid 
atmosphere with 5% CO2/95% O2 at 37
0C until required for experimentation.  
2.4.2 Fibroblast Proliferation Assay  
Cell proliferation was carried out using Cell Counting Kit-8 (WST-8/ CCK-8; ab228554, 
Abcam) according to manufacturer instructions. Cells were seeded in triplicate on a 96-
well plate at a concentration of 5,000 cells/well based off optimisation tests presented in 
the previous section. Cells were incubated for 24 hrs to ensure 80% confluence. Media 
was then removed from each well and replaced with 100 µL of ADSC-EVs at a 
concentration of 1 x 105. Following incubation for 44 hours, 10 µL of CCK-8 dye was 
added to each well. Readings were obtained at a 4 hr incubation time point. Sample 
absorbance was measured at 460 nm using Multiskan GO microplate spectrophotometer 
(Thermo Fisher Scientific). Background absorbance sits around 0.1 – 0.2 nm after 2 hours 
incubation, which was corrected for by preparing control wells of cell culture media 
without cells, and subtract the average absorbance of the control wells from that of the 
other wells. All EV+ absorbance values were normalised to the negative control (Dummy 
EVs) to account for possible effects occurring in standard conditions. Assays were 
carried out in triplicate to ensure technical replication and an n=3 separate ADSC-EV 
samples were assessed.  
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Results from this analysis were repeated in fibroblast cells pre-cultured with known 
(opposing) stimulants of fibrotic activity. Based on previous literature, TGF-β1 and 
TNFα were added to fibroblast-ADSC-EV co-cultures at 5 ng/ml and 10 ng/ml 
respectively (53). Following fibroblast seeding and ADSC-EVs addition, the TGF-β1 and 
TNFα stimulants were added to their respective wells and incubated and analysed via 
CCK-8 the same as the standard proliferation assay.  
2.4.3 Fibroblast wound migration assay  
Fibroblast cell migration was measured by carrying out a scratch wound healing assay. 
A series of optimisation experiments were conducted to assess the optimal seeding 
density for fibroblast migration analysis, with cell concentrations that ranged between 
0.2 x106 and 0.7 x106 cells/well. Optimal seeding density was determined by cells 
reaching 100% confluence. Cells were plated in duplicates onto a 6-well plate at a 
concentration of 0.4 x106 cells/well. Following a 24 hr incubation period, a scratch was 
created through the centre of each well using a 20-200 µL pipette tip. Media was removed 
and cells washed with 1 ml PBS and replaced with 3 ml of ADSC-EV media at 1x 105 
concentration. Photographs of plates were taken in duplicate at 0 hr, 24 hr and 48 hr time 
points using the 10x objective lens. Wound healing was measured as a percentage of 
open wound area using the Tscratch software (CSElab). Following completion of 
standard migration assay, two additional assay preparations were undertaken. This 
included a different set up of the incubation period of ADSC-EVs with fibroblasts (48 
hrs) prior to scratch performed compared to when the ADSC-EVs are added straight after 
the scratch is made (0 hr).   
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2.4.4 Fibroblast mRNA expression levels  
Fibroblast mRNA expression was measured using quantitative reverse transcription PCR 
(RT-qPCR). A series of optimisation experiments were conducted to assess the optimal 
seeding density for fibroblast RNA extraction and qPCR analysis, with cell 
concentrations ranging from 50,000 to 700,000 cells/well observed. Optimal range was 
determined when cells would reach 80-90% confluence 24hrs post seeding and 
subsequently RNA quantification (ng/µL).  
2.4.4.1 RNA extraction  
Each sample duplicate was thawed at room temperature and total RNA was isolated using 
the PureLink TM RNA Mini Kit (InvitrogenTM) following manufacturer’s instructions. In 
brief, samples were initially vortexed to mix thoroughly. Up to 700 µL of the sample was 
transferred to the Spin Cartridge, attached to a Collection tube. Samples were centrifuged 
at 12,000 x g for 15 seconds at room temperature. Following spin the flow-through was 
discarded and spin cartridge was reinserted into the same collection tube. 700 µL of Wash 
Buffer I was added to spin cartridge and centrifuged again at 12,000 x g for 15 secs, 
which flow through was discarded after spin and spin cartridge was inserted into a new 
collection tube. 500 µL of Wash Buffer II (with ethanol) was added to the spin cartridge 
and centrifuged again using same settings. Following spin the flow-through was 
discarded and immediately centrifuged at 12,000 x g for 1-2 minutes to dry the 
membrane. Following centrifugation the collection tube was discarded and the spin 
cartridge inserted into a recover tube (micro centrifuge tube). 30 µL of RNase-Free Water 
was added to the centre of the spin cartridge and incubated at room temperature for 1 
min. The spin cartridge was centrifuged for 2 minutes at full speed at room temp to elute 
the RNA from the membrane to the recover tube.  
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2.4.4.2 cDNA synthesis 
Double stranded cDNA was synthesised from RNA using the SuperScript IV VILO 
Master Mix with ezDNase (Thermo Fisher Scientific) cDNA Synthesis Kit following the 
manufacturer’s instructions. 250 ng of cDNA template was synthesised per RT and NRT 
reaction. 10 µL of gDNA was digested by gently mixing and incubating samples at 370C 
for 2 minutes then briefly centrifuging before putting back on ice. RT control reaction 
mixes were made on ice and added to the 10 µL reaction mixes. No RT control mixes 
(NRTs) were prepared as a control to assess the presence of DNA contamination in RNA 
preparations. Primers were annealed by gently mixing and incubating at 250C for 10 
mins. Reverse transcription of RNA was done by incubating at 500C for 10 mins and 
inactivation of the enzyme by incubating at 850C for 5 mins. cDNA was either ready for 
use or stored in -20 freezer. 
2.4.4.3 qPCR  
Expression of IL-6, TGF-β1, Col1A1, Act2A, FAP (MMP-9, TNFα excluded) were 
measured by real time qPCR using TaqMan Fast Advanced Master Mix, TaqMan Probes 
and the RotorGene 6000 detection system according to the manufacturer’s instructions. 
qPCR analysis was carried out to analyse differences in Fibroblast mRNA expression 
levels between co-cultured ADSC-EVs and Dummy EVs, using TaqMan™ Fast 
Advanced Master Mix (Thermo Fisher Scientific). Gene expression levels of IL-6, TGF-
β1, ACTA2, FAP, COL1A1, MMP-9 and TNFα. As per manufacturer instructions, total 
number of PCR reactions were determined for all cDNA and control samples plated in 
duplicates. TaqMan Fast Advanced Master Mix, TaqMan Assays and cDNA samples 
were thawed on ice and mixed gently or centrifuged respectively before combined to 
reaction mix (Table 2). 
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Table 2 Master Mix template of RT-qPCR analysis 
Per Primer: 1 reaction 
(rx) 
7 rx 
Advanced MM 5 87.5 
Primers 0.5 8.75 
RNase-free water 3.5 61.25 
Total 9 157.5 
 
 
Each master mix was briefly vortexed to mix and centrifuged to bring the reaction 
mixes to the bottom of the tube and eliminate air bubbles. The PCR reaction plate was 
prepared by transferring 9 µL of PCR reaction mix to each well of an optical plate 
(Hard-Shell 384-Well PCR plate; BioRad). 1.0 µL of cDNA template or nuclease-free 
water for NTC was added to each well. The reaction plate was sealed and briefly 
centrifuged to bring the PCR reaction mix to the bottom of the well and eliminate air 
bubbles.  
Each Taqman® assay is specific to an mRNA target and the following targets were 
measured in this experiment: Interleukin-6 (IL-6; Hs00174131_m1; Thermo Fisher 
Scientific, California, United States), MMP-9 (Hs00957562_m1; Thermo Fisher 
Scientific), Collagen type I (COL1A1; Hs00164004_m1; Thermo Fisher Scientific), 
Fibroblast Activation protein (FAP; Hs00990791_m1 ; Thermo Fisher Scientific) 
Transforming Growth Factor-Beta1 (TGF-β1 1; Hs00998133_m1; Thermo Fisher 
Scientific), and alpha-smooth muscle actin (ACTA2; Hs00426835_g1; Thermo Fisher 
Scientific). All mRNA targets were duplexed with housekeeper controls which 
comprised Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Hs99999905_m1; 
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Thermo Fisher Scientific) and RNA Polymerase II Subunit A (POLR2A; 
Hs00172187_m1; Thermo Fisher Scientific). No reverse transcriptase controls were also 
used as a negative control to identify any possible DNA contamination in sample or 
water.  
RT-qPCR cycling conditions were 50oC for 2 mins (Incubation), 95oC for 2 mins 
(Polymerase activation), (95oC for 1 sec, 60oC for 20 secs) for a total of 40 cycles 
including FAM fluorophore, using the Rotor Gene 6000 detection system. mRNA was 
measured using Threshold cycle (Ct) values and the threshold was manually assigned as 
369.77 for the log phase for each run. Criteria for acceptable Ct values and representation 
of weak, moderate or strong expression. 
2.5 Statistical Analysis 
Raw data was organised and stored in in Excel 2016 and a password secured database. 
Following this, data was processed and analysed in Prism v8.0 (GraphPad) for 
development of graphs and statistical analysis. Paired testing was used in this study as 
ADSC-EVs, DEVs and subsequent relationship on fibroblasts was tested in repeated 
measurements. Cell Proliferation was run in triplicates and measured using absorbance 
(nm). Cell migration was also measured with ADSC-EV co-cultured fibroblasts by 
observing differences in % of open wound area at 24 and 48 hr time points. mRNA was 
measured using cycle threshold cycle values (Ct). The threshold used in this study was 




Figure 3 Representative RT-qpCR curves for ADSC-EVs co-cultured fibroblasts 
run in duplicates 
Threshold bar set at 367.9 in order to obtain cycle values and determine relative fold changes 






3.1 Patient Cohort Characteristics  
Three patients were included in this study and provided written informed consent to 
donating their adipose tissue sample. A list of Demographic and clinicopathological 
characteristics of the three included patients. Patients in this study were females who had 
a pathological stage 2 diagnosis of breast cancer. For breast cancer treatment, all patients 
had some previous surgical removal of a part of the breast/s and two had adjuvant 
chemotherapy and adjuvant radiotherapy, while one patient had adjuvant chemotherapy 
only. The majority (n=2) had wide local excision and axillary dissection which preserves 
a larger area of the breast, while one patient had a mastectomy surgery. These patients 
had breast cancer treatment within 2 years (+ 1) of their AFG surgery. The mean age of 
the cohort of analysed samples (n=3) was 52 years old (+ 7). Our three patients included 
two NZ Pākehā (European) and one NZ Māori. These patients were not on any regular 
medications such as Insulin, Metformin and Gliclazide and did not present with the 
following medical history; type 1 diabetes, type 2 diabetes, hypertension or any prior 
malignancy. Tikanga were followed included disposal of tissue samples with a karakia 
upon patient request.  
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3.2 ADSC Isolation and Confirmation  
Following tissue digestion cells were counted and mean viability was measured. The 
mean cell count of the patients (n=3) was (2.83 + 2.13 x 106 cells/mL) and mean cell 
viability (59.7 + 3.8 %). ADSCs purity was previously confirmed by a student in the lab 
(Emma Symonds). Briefly, observations in cell culture show ADSCs display typical 
morphology of triangular, stretched out bodies (52). ADSCs pluripotent characteristic 
was tested as ADSCs that differentiated into adipocytes showed positive Oil-Red-O 
staining, indicating the presence of lipid bodies. ADSCs were also tested for pluripotency 
characteristics such as differentiation into osteoblasts which stain positive for Alizarin 
Red, indicating the presence of calcium deposits (53). Morphological differences 
observed in both differential states of ADSCs such as size and roundness further allow 
for confirmation of ADSC isolation from tissue. In addition, known ADSC markers 
(CD166+, CD105+, CD10+) were measured with known Monocyte markers that were 
not expected to be expressed by ADSCs (CD31-, CD14-) using flow cytometry (52). 




3.3 EV Isolation and Confirmation 
EV concentration and size were measured for each of the three patient samples (Table 
3). Mean particle size (diameter nm) and concentration (particles/mL) was recorded for 
each patient. The mean particle size in our ADSC-EV cohort was (269 + 13.23 nm) and 
mean particle count (concentration) 5.89 x106 particles/mL. EV presence was also 
confirmed by observing a double membrane in cryoTEM analysis (Fig 5) and Western 
Blotting protein expression analysis which was confirmed by a previous student.  
  
 
Table 3 ADSC-EV size and concentration 




AD23 259 + 94.4 6.88 x108 
AD35 284 + 124.9 4.72 x108 





Figure 4 Concentration versus particle diameter histograms of particles measured 
using TRPS 
Representative histogram of the concentration (particles/mL) versus particle diameter in 
nanometres (nm). Particles were isolated using SEC columns from ADSC cell culture 
media and the first four fractions were pooled and characterised using TRPS on the 
qNano Gold. The x axis measured particle diameter (nm) and the y axis shows the 




Figure 5 Cryo-TEM image of EVs isolated from ADSCs 
Representative Cryo-TEM image of EVs isolated from ADSCs. Showcasing their double 
membrane characteristic. Samples were prepared at the Wellington Campus and sent 
down to Dunedin for imaging.  
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3.4  Fibroblast Proliferation in co-culture with ADSC-EVs and DEVs 
Cell proliferation by CCK-8 (Fig 6) showed no difference in the mean absorbance of 
fibroblasts co-cultured with ADSC-EVs (0.8320 + 0.340 nm) compared to DEV co-
























Figure 6 ADSC-EV treated fibroblasts proliferate at the same rate as DEVs 
Cell proliferation was measured as CCK-8 absorbance levels (nm) of Dummy EVs 
(DEVs) and Adipose-derived stem cell-Extracellular vesicles (ADSC-EVs). Proliferation 
does not differ between the ADSC-EV treated and DEV control fibroblasts. Results are 
expressed as mean + SD, and done in triplicate (n=3). These groups were analysed using 




3.5  Effect of ADSC-EVs on fibroblast proliferation in presence of 
TNF-α and TGF-β1 
As seen in 3.4 cell proliferation is not altered in ADSC-EV co-cultured fibroblasts 
compared to their control counterparts. The breast microenvironment may exhibit a pro-
inflammatory and pro-fibrotic environment after breast cancer treatment. We therefore 
wanted to assess whether ADSC-EVs have any effect when the cells are already under a 
stressed or polarised condition. ADSC-EVs effect on cell proliferation in the presence of 
TNF- α and TGF-β1 was assessed in one experimental replicate, therefore no statistical 
analysis was undertaken. An interesting initial observation is that a small difference exits 
between TGF-β1 stimulation when ADSC-EVs are added, however further investigation 























































Figure 7 ADSC-EVs effect on fibroblast proliferation when incubated with TGF- 
β1 and TNFα stimulants 
Cell proliferation was measured as CCK-8 absorbance levels (nm) of Dummy EVs 
(DEVs) and Adipose-derived stem cell-Extracellular vesicles (ADSC-EVs) in fibroblasts 
incubated with either Transforming Growth Factor-Beta (TGF-β1; 5 ng/ml) or Tumour 
Necrosis Factor alpha (TNF-α; and 10 ng/ml) for 48 hrs. A Vehicle Control (Veh) was 
used as a technical control. Proliferation does not differ between the ADSC-EV treated 
and DEV control fibroblasts except a small observation with TGF-β1 stimulated 
fibroblast cells. Results are only represented by one experimental replicate and therefore 





3.6 ADSC-EVs Effect on Fibroblast Cell Wound Migration  
3.6.1 ADSC-EVs Have No Effect on Fibroblast Wound Migration 
Cell migration was measured as a percentage of open wound area at 24 hr and 48 hr time 
points and normalised to initial open wound area (0hr scratch). In both fibroblasts with 
ADSC-EVs or DEVs, cell migration was observed over time. However, there was no 
statistically significant difference between the DEVs (0.38 + 0.06%) and ADSC-EVs 
(0.37 + 0.16%) in open wound area when observed under the microscope at 24 hrs after 
the scratch was performed (p=0.898). A similar result was observed at the 48 hr time 
point, no significant difference between ADSC-EV (0.08 + 0.10) and DEVs (0.04 + 






Figure 8 ADSC-EVs effect on cell wound migration when seeded 0 hrs after 
scratch wound 
A) Wound migration assay results showing the difference between ADSC-EVs cultured 
fibroblast and DEV fibroblast migration at the 24hr and 48hr time point. No significant 
difference in cell migration when ADSC-EVs are incubated with fibroblasts shortly after 
wound scratch is performed. Wound migration is displayed as % open area. Results are 
expressed as mean + SD, results are done in duplicate for ADSC-EVs (n=3).  Individual 
groups were analysed using a t-test. B) Representative wound healing in ADSC-EV and 
DEV co-cultured fibroblasts. Images taken at 4x objective. 
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3.6.2 Cell migration with ADSC-EVs seeded 48hrs before scratch and Fibroblasts 
seeded at a lower density  
To determine whether a longer incubation of ADSC-EVs with fibroblasts will effect 
migration, we seeded ADSC-EVs with fibroblasts 48 hrs prior to scratch wound. Another 
experimental change is the lower seeding density of fibroblasts to 0.1 x 106 cells/well. It 
appears that relative cell migration is not different between ADSC-EV and DEV co-
cultures at both the 24 hr and 48 hr time points, however is trending towards a slower 




Figure 9 ADSC-EVs effect on cell migration when incubated with fibroblasts for 
48 hrs prior to scratch 
Wound migration assay results showing the difference between ADSC-EVs cultured 
fibroblast and DEV fibroblast migration. No significant difference in cell migration when 
ADSC-EVs are incubated with fibroblasts before wound is introduced. Wound migration 
is displayed as % open area. Results are expressed as mean + SD, results are done in 
duplicate for ADSC-EVs (n=3).   
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3.7 ADSC-EVs May Promote a Pro-inflammatory Environment in 
Fibroblasts 
3.7.1 Gene Expression 
Gene expression was measured as a relative fold change to DEV expression level after 
48 hr incubation of ADSC-EVs. Overall there was no statistically significant difference 
in expression levels of all genes compared to DEVs.  
On visual inspection of the graphs there are two genes of interest that show a numerical 
difference in expression levels. Fibroblasts co-cultured with ADSC-EVs showed an 
increase in pro-inflammatory IL-6 marker expression when compared to DEVs (6.556 + 
6.512, p= 0.2775: Hs00174131_m1). In comparison, a decrease in pro-fibrotic ACTA2 
marker expression level was observed in fibroblast cultured with ADSC-EVs compared 
to DEVs (0.5328 + 0.3200, p= 0.1272: Hs00426835_g1). The remaining markers showed 
no numerical differences in expression between the two groups. (FAP: 2.048 + 2.27, p= 
0.5080; Hs00990791_m1; COL1A1: 1.044 + 0.8836, p=0.9392, Hs00164004_m1; TGF-
β1: 1.131 + 0.4738, p>0.05, Hs00998133_m1). 
3.7.2 Variation in Fibroblast Gene Expression  
Across the different genes analysed there seemed to be a varying effect between the three 
ADSC-EV co-cultures. More variation was observed in fibroblast gene expression when 
cultured with ADSC-EVs compared to DEVs based on standard deviation levels. The 
individual expression of each gene in fibroblasts co-cultured with ADSC-EVs are shown 
in table 3. The variation is observed in IL-6 relative expression levels in two ADSC-EV 
co-cultures that showed an increase fold change and then one co-culture showing no 
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change in fibroblast expression compared to DEVs. Similar variation is shown in TGF-
β1 relative expression levels in two ADSC-EVs co-cultures that show a decrease fold 
change and then one EV co-culture showing an increase (table 4).  
Therefore, variable changes in the expression of the pro-inflammatory and pro-fibrotic 
markers were observed in the three fibroblast-ADSC-EV co-cultures and these results 
are intriguing to know that it is not always the same ADSC-EV patient that is causing 





Figure 10 ADSC-EV co-cultured fibroblasts express different levels of pro-
inflammatory and profibrotic markers. 
RT-qPCR was performed in duplicate and fold changes were normalised to two different 
housekeeping genes (Glyceraldehyde 3-phosphate dehydrogenase; GAPDH and RNA 
Polymerase II Subunit POLR2A). 8.A,B,C,D and E) relative expression levels of key 
genes involved in pro-inflammatory expression (IL-6 and FAP) or pro-fibrotic 
expression (ACTA2, TGF-β1 and COL1A1). Results are expressed as mean + SD, 
experiments were performed in triplicate repeats (n=3).  
 
 
Table 4  Inter-individual variation across ADSC-EVs based on individual fold change 
 IL-6 FAP ACTA2 TGF-β1 COL1A1 
AD23  No change No change    
AD35       




4 Discussion  
4.1 Key Findings  
The aim of this study was to investigate the behavioural and mRNA expression profile 
of fibroblasts when cultured with ADSC-EVs. This is important in the context of fat 
grafting retention because fibroblasts play an important role in wound healing and 
regulating the breast ECM. The key findings include; 1) ADSC-EVs had no significant 
observed effect on fibroblast proliferation and migration; 2) ADSC-EVs had no 
statistically significant effect on fibroblast mRNA expression levels but preliminary data 
suggests they may up-regulate pro-inflammatory mRNA markers; 4) There is 
heterogeneity in the effect produced by ADSC-EVs prepared from different patient 
samples 
To our knowledge, this is the first study to report on the effects of ADSC-EVs on human 
fibroblasts in culture and provides valuable information in the context of fat grafting.  
 
4.2 Behavioural Analysis of Fibroblasts with ADSC-EVs 
We saw no significant changes in cell proliferation and migration in ADSC-EV co-
cultured fibroblasts compared to DEVs. In response to tissue damage, fibroblasts are 
activated and respond by migrating, to the site of injury to proliferate and subsequently 
secrete ECM structures. At increased levels this can result in fibrosis or scar formation 
in the breast (54). This can result in significant pain, tissue deformation and 
complications for women who have already been subjected to immense stress through 
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breast cancer, diagnosis and treatment. With ADSC-EVs as a possible treatment for graft 
retention, these results indicate that ADSC-EVs do not exert an overactive phenotype of 
fibroblasts and formation of scar tissue could be reduced as a result of ADSC-EV therapy. 
The breast cavity is a potentially highly inflammatory and pro-fibrotic environment post 
breast cancer treatment, we therefore also wanted to look at the ability of ADSC-EVs to 
affect fibroblasts that have been stimulated with TNFα or TGF-β1. Tumour necrosis 
factor-alpha (TNFα) is an inflammatory cytokine produced in the wound healing process 
(55, 56).  TNFα contributes to the stimulation of fibroblast proliferation which in turn 
promotes their role in the recruitment of other necessary cell types such as endothelial 
and macrophages to the injury site for further response (57). Transforming Growth 
Factor-Beta 1 (TGF-β1) is a strong activator of connective tissue synthesis and can 
regulate growth and differentiation of cells (58). Therefore, the transition from quiescent 
fibroblast to activated myofibroblast is influenced by TGF-β1 stimulation. Researchers 
have shown that TGF-β1 promotes proliferation, collagen formation and differentiation 
of dermal (59). In contrast our results showed no observable change in proliferation in 
both TGF-β1 and TNFα stimulated fibroblasts with the addition of ADSC-EVs. 
However, we cannot conclude on these results as limitations outside of the researchers 
control meant further biological replicates could not be conducted. Factors such as the 
University of Otago, Wellington Campus closure and an inaccessible laboratory during 
COVID-19 lockdown impacted our ability to complete this work. The next step of this 
study would be to complete the investigation on ADSC-EVs effect on fibroblast 




4.3 Fibroblast Gene Expression Levels After the Addition of ADSC-
EVs 
In this study there were no significant differences in expression levels across all genes 
measured. However, we did see a quantitative difference in increased IL-6 gene 
expression levels and in decreased ACTA2 gene expression levels in fibroblasts co-
cultured with ADSC-EVs. IL-6 is an inflammatory cytokine released upon tissue damage 
and usually activates fibroblast activity. Alpha Smooth Muscle Actin (ACTA2) is a 
fibrotic marker, and the key indicator of fibroblast activation to the activated 
myofibroblast phenotype, and thus associated with the production and synthesis of ECM 
proteins and structures. Through the upregulation of inflammatory markers such as IL-6 
and downregulation of pro-fibrotic markers such as ACTA2, this would indicate that 
ADSC-EVs promote fibroblasts as a pro-inflammatory cell type. If a pro-inflammatory 
environment is stimulated in fibroblasts during or post fat grafting, then ADSC-EVs may 
stimulate an inflammatory response from fibroblasts resulting in reabsorption of the fat 
graft through recruitment of immune cells. This is relevant to our study as we would need 
to know if there is consequent down regulation of other expression markers in fibroblasts 
during either a pro-inflammatory or pro-fibrotic condition. Therefore an appropriate next 
step for this study will be to repeat this gene expression analysis with TNFα and TGF-β1 
treatment to investigate ADSC-EV effects on expression levels in known fibroblast 
stimulated environments. This study is statistically underpowered with n=3 because of 




4.4 Inter-Individual Variability amongst our ADSC-EVs  
This study observed variable ADSC-EV effects on fibroblast expression levels across the 
majority of the genes investigated. IL-6 gene expression levels had a large quantitative 
increase from two ADSC-EV patients but also a minimal quantitative increase from one 
patient. An opposite effect was observed in our TGF-β1 expression levels, which had 
some quantitative decrease from two ADSC-EV patients but one patient showed an 
increase. Finally, ADSC-EV effects on fibroblast expression levels of COL1A1 showed 
a variable effects such that a mixture of increased, decreased and no relative change was 
observed across the three patient-derived samples. The variability in ADSC-EV effect in 
both pro-inflammatory and pro-fibrotic markers suggests that ADSC-EVs do not effect 
fibroblasts expression levels in the same way. This could mean that fibroblast gene 
expression levels and correlating phenotypic activity could be activated in one patient 
but down-regulated in another. To further develop ADSC-EVs as a therapy we would 
need to develop methods to make their effect consistent. ADSC-EV variation in 
expression level could be due to the patient tissue in which the ADSC-EVs in this study 
came from.  
When you extract cells from patient tissue samples you retrieve cells that are products of 
that microenvironment in which they resided in and as the microenvironment is dynamic 
and complex these can be different between patients. Furthermore, there could be 
potential effects on ADSC phenotype and activity from underlying genetics or 
epigenetics of the individual as well as consideration of BMI and whether patients with 
higher BMI could present ADSCs in a more inflammatory state. Another consideration 
for this Inter-individual variation could be the heterologous nature of our experiments, 
meaning our ADSCs and subsequent derived EVs have come from a different patient to 
the fibroblast cell line we are investigating.  A next step from this heterologous fat 
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grafting in vitro would be to perform autologous experiments, whereby fibroblasts are 
isolated from the same patient our ADSCs are collected from. This will provide the study 
with more clinically relevant results for fat grafting procedures.  
4.5 Relevance to fat grafting  
With advancements in breast cancer treatment, more women are now surviving from 
breast cancer and so there is a significant amount of patients opting in for breast 
reconstruction. AFG is an increasingly popular option, however low and varying 
retention rates are a major caveat of fat grafting and need to be improved. Improving fat 
grafting can provide a more equitable breast reconstruction option for breast cancer 
patients in Aotearoa.  
From our findings, there is no clear evidence of a change in function of fibroblasts with 
ADSC-EVs at this stage. This suggests that ADSC-EVs do not stimulate fibroblasts to 
differentiate into the activated myofibroblast phenotype and thus will not stimulate 
fibroblasts into an overly activated phenotype where potential issues in wound healing 
can occur such as fibrosis and scar deformation. However, with the potential up 
regulation in pro-inflammatory mRNA markers in fibroblasts there is also the possibility 
that this could further stimulate an immune response and rejection of the implanted fat 
graft.  
Overall ADSC-EVs did not appear to stimulate fibroblast function into its activated state. 
We therefore hypothesise, that ASDC-EVs could have a regulatory role in fibroblasts 
trans-differentiation to a myofibroblast and potentially activation. This potential 
regulation of fibroblast activation will therefore supress the excessive multiplication of 
fibroblast cells and over-synthesis of ECM and scar formation at the site of fat graft 
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implantation. A reduced amount of scar tissue correlates to a less structurally deformed 
and compromised tissue which helps in the context of rebuilding a breast using AFG.  
A final consideration is that we are working in a breast cavity that has previously 
undergone breast cancer treatment. Radiation therapy, following surgery has shown to 
cause increased inflammation levels causing recruitment of other cell types (60). This 
shows that fat grafting occurs in the breast tissue that already exhibits a pro-fibrotic 
microenvironment. Therefore it is still unclear if ADSC-EVs will have a different effect 
on fibroblast activation in a setting where they may already be stimulated or be effected 
by other cells in the microenvironment.  
4.6 Future Directions  
In order to further understand the role of ADSC-EVs on fibroblast function it would be 
an beneficial for the study to continue and complete the investigation of ADSC-EV 
effects on fibroblasts stimulated under the pro-inflammatory or fibrotic environment as 
we believe the breast cavity will be in a similar state. As we predict that ADSC-EVs may 
have an active role in regulating the over-activation phenotypes of fibroblasts it would 
also be beneficial to assess any effects in gene expression levels as well for further 
validation of results and potentially determine other regulatory factors involved.  
This study is part of a larger study that is investigating what potential modulatory role 
ADSC-EVs have in the tissue microenvironment to augment fat graft retention in patients 
undergoing AFG. This includes investigating the effects that ADSC-EVs have on 
macrophages, another key cell type involved in inflammatory and wound healing 
responses (61). The results from our study could be used to determine any correlation in 
ADSC-EV modulatory effect on fibroblast and macrophage cell behaviour. Macrophages 
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are involved in both the inflammatory response but also tissue regeneration through the 
secretion of TGF-β1 and activation of fibroblasts (62), therefore comparing results of 
ADSC-EVs effect on macrophage and fibroblast activity would be helpful in not only 
characterising ADSC-EV effects on the individual cell types but also link in to the 
development of a 3D culture model.   
The cell culture models utilised in this study are well documented and allow for 
comparison of methodology and results. However, these models use a 2D monolayer 
which is not representative of the multicellular 3D microenvironment that makes up a 
tissue. The next step will be to develop 3D models to study fibroblast and other cell 
activity in a more representative culture. However a 2D cell culture model was adopted 
for this study as there is currently minimal knowledge on ADSC-EVs role in fat graft 
retention and therefore it is important to analyse the effects on individual cells before 
looking at the effects of other cell types involved in the tissue repair and regeneration 
processes in AFG. A 3D cell model would be beneficial to investigate next.  
As we proposed that the breast cavity is a pro-fibrotic and pro-inflammatory tissue, where 
fibroblasts are activated from breast cancer treatment in wound healing, it would be 
beneficial for the study to investigate ADSC-EV effects in a breast fibroblast model to 
further facilitate relevant in vivo results and outcomes.  
Furthermore, fibroblasts cells mentioned previously are not the only potential residing 
cells in the breast cavity and so once the fibrotic phenotype of ADSC-EV co-cultured 
fibroblasts are confirmed it would then be necessary to assess the safety profile of ADSC-
EVs by carrying out the same protocols and analyses with breast cancer cells and also 
look at the use of an invasion assay. This is important when we consider that AFG for 
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breast reconstruction occurs in a former tumour bed and there are concerns around 
ADSC-EVs potential for tumorigenesis resurgence.  
4.7 Strengths and Limitations  
A strength of this study is that we used primary ADSC-EVs from patients who were 
having fat grafting procedures. Additionally this study utilised a human cell model with 
both ADSCs and fibroblasts. The use of a primary ADSC culture model allowed us to 
assess their effect on skin fibroblast activity and therefore being more clinically relevant 
than if an ADSC immortalised cell line was used.  However the use of primary cells 
require special maintenance as they are prone to higher risk of mycoplasma bacteria 
contamination and have finite growth compared to cell lines (63). 
A major limitation in our ability conclude ADSC-EVs variable effects on fibroblasts was 
due to the low sample size (n=3). Increasing the statistical power would allow us to draw 
more conclusive ideas around the role ADSC-EVs may have on fibroblast activity. 
Across our gene expression measurements, we observed variable effects of well-known 
mRNA markers of fibroblast activation, however, these findings were not statistically 
significant. Because of our low sample size, it was hard to determine if the quantitative 
change in expression levels was of true variance of ADSC-EVs effect or if there is a 
potential promoting pathway that just was not visible with only the three patients 
included in this study.    
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4.8 Conclusions  
Low graft retention in AFG is largely due to a failure of the graft to integrate into the 
environment in which it is placed, with losses ranging from 20 – 80%. This results in 
inadequate vascularisation of the tissue, cell death and fibrosis. Overall this is an issue of 
communication between the various cell types in the donor and recipient tissue to create 
a viable microenvironment. Therefore, Improving fat graft retention in AFG will provide 
more of an equitable breast reconstruction option for all female breast cancer patients.  
The overall aim of this study was to determine the role that ADSC-EVs have on 
individual cell types in the breast tissue in the larger context of studying their potential 
role in fat graft retention.  
We demonstrated that ADSC-EVs have a potential to promote a pro-inflammatory 
environment in fibroblasts and that our data show a variation in ADSC-EV effects on 
expression levels compared to their DEVs counterparts. We also demonstrated that 
ADSC-EVs did not change fibroblast activity and therefore  
While our first hypothesis cannot be fully confirmed, it cannot yet be determined whether 
ADSC-EVs modulate the pro-fibrotic phenotype of fibroblasts, this study provides a 
good starting point for future research to further elucidate, the fibrotic phenotype of 
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